Sign in Subscribe
COVID-19

FDA Vaccine Chief Restricts Approval of COVID-19 Vaccines, Ignoring Government Scientist Recommendations

Strategic Insights

— 2 min read

The FDA's vaccine chief, Dr. Vinay Prasad, has intervened to restrict the approval of COVID-19 vaccines from Moderna and Novavax, disregarding recommendations from government scientists. In a five-page memo, Prasad explained that the benefits of the vaccines must be reconsidered in light of falling rates of death and hospitalization, and the possibility of vaccine side effects. This is the latest in a series of vaccine restrictions imposed by Health Secretary Robert F. Kennedy Jr., who has long questioned the benefits of vaccines. Prasad's decision will limit the approval of the vaccines to those who face special risks from the virus, including seniors and children and adults with underlying medical issues.

Key Takeaways:

  • The FDA's vaccine chief, Dr. Vinay Prasad, has restricted the approval of COVID-19 vaccines from Moderna and Novavax, ignoring recommendations from government scientists.
  • Prasad's decision is based on the falling rates of death and hospitalization from COVID-19, and the possibility of vaccine side effects.
  • The restrictions will limit the approval of the vaccines to those who face special risks from the virus, including seniors and children and adults with underlying medical issues.
  • The decision is part of a series of vaccine restrictions imposed by Health Secretary Robert F. Kennedy Jr., who has long questioned the benefits of vaccines.
  • The FDA's vaccine center was led by Dr. Vinay Prasad, who was hired in May after the previous director, Dr. Peter Marks, was forced to resign over disagreements with Kennedy.
  • Prasad has worked with FDA Commissioner Mark Makary on new guidelines that will limit approvals of future COVID boosters to higher-risk Americans, mainly seniors and those with medical conditions like asthma and obesity.

Statistics:

  • COVID-19 remains a public health threat, resulting in 32,000 to 51,000 U.S. deaths and more than 250,000 hospitalizations since last fall, according to the Centers for Disease Control and Prevention.
  • Most at risk for hospitalization are seniors and children under 2 -- especially infants under 6 months.
  • 30,000 adults participated in a study on Novavax's vaccine, which concluded that "the risk-benefit assessment for this vaccine technology remains favorable."
  • The FDA has finalized new warning labeling about the risk of myocarditis, a rare form of heart inflammation, on shots from Moderna and Pfizer.

Sources:

  • AP: "FDA vaccine chief restricts approval of Moderna, Novavax COVID shots"
  • The New York Times: "FDA Doc

Agid Shows Vaccine Benefits Remain Strong"

  • FDA: "Notice of Public Hearing to Discuss COVID-19 Vaccine Products"
  • CDC: "COVID-19 Cases and Deaths by Age Group"
  • Howard Hughes Medical Institute: "Support for Science Education"
  • Robert Wood Johnson Foundation: "Support for Public Health Initiatives"

Read more